GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (XCNQ:CGN) » Definitions » Momentum Rank

Cognetivity Neurosciences (XCNQ:CGN) Momentum Rank : 0 (As of Jun. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Momentum Rank?

Cognetivity Neurosciences has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Cognetivity Neurosciences Momentum Rank Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognetivity Neurosciences (XCNQ:CGN) Business Description

Traded in Other Exchanges
Address
800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.
Executives
Ravinder Kang Director

Cognetivity Neurosciences (XCNQ:CGN) Headlines

No Headlines